Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. | In patients with BTK-pretreated chronic lymphocytic leukemia, AbbVie and Roche’s Venclexta is the drug to beat. But no companies had taken a daunting head-to-head challenge—until Eli Lilly made the leap of faith with its Jaypirca.
TL;DRAI
Jaypirca + venetoclax-rituximab cut CLL progression/death risk by 45.3%; second-line post-BTK patients gained 67.7% PFS benefit (BRUIN CLL-322). Strong efficacy with low toxicity reshapes BTK inhibitor market dynamics and biotech M&A strategy for oncology-focused acquirers.
1,138 words~5 min read
